A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Phase 3 Recruiting
1,000 enrolled
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Phase 3 Recruiting
400 enrolled
OPERA-02
Phase 3 Recruiting
1,000 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Phase III Study of JSKN016 Versus Treatment of Physician's Choice in Patients With Triple-Negative Breast Cancer Who Have Failed Standard of Care
Phase 3 Recruiting
364 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Phase 1 Recruiting
399 enrolled
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
Phase 1/2 Recruiting
768 enrolled
DELTA-101
Phase 1 Recruiting
396 enrolled
An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Solid Tumors
Phase 1 Recruiting
86 enrolled
REPOWER
Recruiting
3,000 enrolled
Study of INCB123667 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
604 enrolled
A Study of XMT-1660 in Participants With Solid Tumors
Phase 1 Recruiting
319 enrolled
Adjuvant WIDER
Phase 3 Recruiting
1,400 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Phase 1 Recruiting
60 enrolled
Close2HER
Recruiting
100 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
Phase 1 Recruiting
694 enrolled
CAMBRIA-1
Phase 3 Recruiting
4,300 enrolled
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1 Recruiting
383 enrolled
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 Recruiting
1,530 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 Recruiting
392 enrolled
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Phase 1 Recruiting
240 enrolled
A First-in-human, Clinical Trial Assessing the Safety of ES2B-C001-S01 With or Without [Adjuvant] in Patients With HER2-expressing Metastatic Breast Cancer.
Phase 1 Recruiting
40 enrolled
A Phase IIa Study to Evaluate NBQ72S
Phase 2 Recruiting
10 enrolled
TroFuse-011
Phase 3 Recruiting
1,000 enrolled
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Phase 3 Recruiting
2,400 enrolled
ASPEN-09-03
Phase 2 Recruiting
120 enrolled
A Phase 1 Study of 68Ga-R11228 and 177Lu-R11228 in Breast Cancer
Phase 1 Recruiting
62 enrolled
optINAVO
Phase 2 Recruiting
80 enrolled
KOMODO-1
Phase 1 Recruiting
96 enrolled
SELECT-2CAR
Phase 1/2 Recruiting
72 enrolled
HLD-0117
Phase 1 Recruiting
33 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Phase 3 Recruiting
250 enrolled
CYCAD-1
Phase 1/2 Recruiting
564 enrolled
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 Recruiting
162 enrolled
panSOHO
Phase 2 Recruiting
111 enrolled
SIGNAL-ER 101
Phase NA Recruiting
725 enrolled
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Phase 3 Recruiting
1,800 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
ELAINEIII
Phase 3 Recruiting
500 enrolled
BRIA-ABC
Phase 3 Recruiting
404 enrolled
A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer
Phase 1/2 Recruiting
100 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled